News

Blood biomarkers may help to predict poor outcomes in babies born with a rare congenital defect of the diaphragm that often leads to pulmonary hypertension (PH). The seven biomarkers, identified by researchers in Germany and evident in the blood within 24 hours of birth, were associated with a…

Patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) and their caregivers can now access myMentor, a U.S. support program established by Bayer. The company launched the program at the International PH Conference and Scientific Sessions that recently concluded in Orlando, Florida, and was organized by…

Pulmonary arterial hypertension (PAH) affects the health of the gut’s microbial community, or microbiota, with an imbalance possibly being a factor in disease progression, a small study performed in a rat PAH model reports. The study, “Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome,” was published in the…

An enzyme called NOX4 appears to have a crucial role in the blood vessel remodeling that can lead to pulmonary hypertension (PH) in patients with chronic obstructive pulmonary disease (COPD), a study in China reports. The research, “NOX4 expression and distal arteriolar remodeling correlate with pulmonary hypertension…

Adempas (riociguat), an approved therapy for adults with pulmonary hypertension (PH), may hold promise for treating newborns with bronchopulmonary dysplasia (BPD) and PH, results of an animal study show. These findings suggest that Adempas’ use in babies…

Vivus Biopharmaceuticals’ investigative therapy VI-0106 for pulmonary arterial hypertension (PAH) showed a favorable pharmacokinetic profile in healthy volunteers in a Phase 1 trial. Pharmacokinetics refers to how a medication is absorbed, distributed, metabolized, and eliminated from the body. VI-0106 is a soft gel formulation of tacrolimus, an immunosuppressant under…

An easy and simple tool called the incremental shuttle walk distance test, or ISWD, appears promising to identify early signs of pulmonary hypertension (PH), according to a new study. The results showed that patients with early PH who don’t show major disease symptoms already have a significant decrease in…

A certain protein found on white blood cells, which plays a role in causing pulmonary arterial hypertension (PAH), may be a potential new therapeutic target, a study in mice and humans suggests. The study, “Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice,” was published…

Exercise has a wide range of benefits for people with pulmonary hypertension (PH), improving physical capacity and quality of life, among other advantages, according to a recent review study. Researchers emphasize, however, that PH patients should only exercise under the guidance of PH and rehabilitation specialists. The study, “…

Women who have hypertension or preeclampsia, a more severe condition that leads to damage in the internal organs, during pregnancy have a two- to three-fold higher risk of developing hypertension later in life. Also, 70 percent of them have higher rates of type 2 diabetes and 30 percent have…

Infusions of large doses of intravenous iron may be a safe treatment approach for patients with low oxygen levels in their blood due to pulmonary hypertension (PH) and/or congenital heart disease (CHD), a study reports. The study, “Use of intravenous iron in cyanotic patients with congenital heart disease…

Roivant recently announced the launch of two new business units, Roivant Pharma and Roivant Health, as well as the creation of Altavant Sciences, a company that will focus on developing new therapies, including RVT-1201 as a potential treatment for pulmonary arterial hypertension (PAH). As part of its long-term strategy, Roivant…